$-0.10 EPS Expected for DexCom, Inc. (DXCM)

October 14, 2018 - By Linda Rogers

DexCom, Inc. (NASDAQ:DXCM) LogoInvestors sentiment increased to 1.22 in Q2 2018. Its up 0.07, from 1.15 in 2018Q1. It improved, as 21 investors sold DexCom, Inc. shares while 82 reduced holdings. 46 funds opened positions while 80 raised stakes. 88.54 million shares or 9.89% less from 98.26 million shares in 2018Q1 were reported.
Art Ltd Liability Company has invested 0.13% in DexCom, Inc. (NASDAQ:DXCM). Manufacturers Life Insur Co The has 2,406 shares for 0% of their portfolio. Dafna Cap Management Ltd Limited Liability Company reported 55,000 shares. Trexquant Investment Limited Partnership stated it has 0.38% in DexCom, Inc. (NASDAQ:DXCM). Gam Hldgs Ag accumulated 0.02% or 4,823 shares. Brown Advisory reported 0.93% of its portfolio in DexCom, Inc. (NASDAQ:DXCM). Huntington Savings Bank holds 40 shares. Synovus Fin Corporation stated it has 0% in DexCom, Inc. (NASDAQ:DXCM). 655,324 were reported by Citadel Advsrs Limited Company. Moreover, M&T Bancorporation has 0% invested in DexCom, Inc. (NASDAQ:DXCM) for 4,619 shares. Citigroup Inc has 4,320 shares. Vanguard holds 0.03% or 7.13 million shares in its portfolio. Aperio Gp Limited Liability Company accumulated 24,649 shares. Numerixs Invest Tech reported 0.14% of its portfolio in DexCom, Inc. (NASDAQ:DXCM). Bokf Na invested 0.02% in DexCom, Inc. (NASDAQ:DXCM).

Since April 16, 2018, it had 0 buys, and 37 selling transactions for $42.35 million activity. MOY JEFFREY had sold 59,193 shares worth $5.47M on Thursday, June 28. Another trade for 1,832 shares valued at $263,360 was made by ACE HEATHER S on Monday, September 10. On Friday, August 24 Leach Jacob Steven sold $2.85M worth of DexCom, Inc. (NASDAQ:DXCM) or 20,577 shares. SAYER KEVIN R also sold $1.42M worth of DexCom, Inc. (NASDAQ:DXCM) shares. $1.55M worth of stock was sold by Murphy Patrick Michael on Friday, August 10. $858,974 worth of DexCom, Inc. (NASDAQ:DXCM) was sold by GREGG TERRANCE H on Tuesday, May 15.

Analysts expect DexCom, Inc. (NASDAQ:DXCM) to report $-0.10 EPS on November, 7.They anticipate $0.07 EPS change or 233.33 % from last quarter’s $-0.03 EPS. After having $-0.10 EPS previously, DexCom, Inc.’s analysts see 0.00 % EPS growth. The stock increased 3.82% or $4.67 during the last trading session, reaching $127.07. About 1.08 million shares traded. DexCom, Inc. (NASDAQ:DXCM) has risen 98.67% since October 14, 2017 and is uptrending. It has outperformed by 83.05% the S&P500.

DexCom, Inc. (NASDAQ:DXCM) Ratings Coverage

Among 11 analysts covering DexCom (NASDAQ:DXCM), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. DexCom had 19 analyst reports since May 3, 2018 according to SRatingsIntel. The firm earned “Equal-Weight” rating on Thursday, October 11 by Morgan Stanley. The firm has “Overweight” rating given on Thursday, August 23 by Stephens. The stock of DexCom, Inc. (NASDAQ:DXCM) earned “Outperform” rating by Raymond James on Monday, July 2. The company was maintained on Thursday, August 2 by Canaccord Genuity. On Friday, June 8 the stock rating was upgraded by J.P. Morgan to “Buy”. As per Wednesday, September 12, the company rating was upgraded by Northland Capital. Berenberg upgraded the stock to “Buy” rating in Monday, August 6 report. As per Thursday, August 2, the company rating was maintained by BMO Capital Markets. The stock has “Buy” rating by Bank of America on Wednesday, August 15. JP Morgan upgraded the stock to “Overweight” rating in Friday, June 8 report.

DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. The company has market cap of $11.23 billion. The firm offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. It currently has negative earnings. The Company’s products include DexCom G4 PLATINUM system for continuous use by adults with diabetes; DexCom G4 PLATINUM with Share, a remote monitoring system; and DexCom G5 Mobile, a CGM system that directly communicates to a patient's mobile and its data can be integrated with DexCom CLARITY, which is a next generation cloud reporting software for personalized, easy-to-understand analysis of trends to improve diabetes management.

Another recent and important DexCom, Inc. (NASDAQ:DXCM) news was published by Nasdaq.com which published an article titled: “Strange: Bullish DXCM Analysts Actually See -2.12% Downside” on September 17, 2018.

DexCom, Inc. (NASDAQ:DXCM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News